KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Charles River Laboratories International (CRL) EBIAT (2016 - 2025)

Charles River Laboratories International has reported EBIAT over the past 17 years, most recently at -$278.5 million for Q4 2025.

  • Quarterly results put EBIAT at -$278.5 million for Q4 2025, down 29.82% from a year ago — trailing twelve months through Dec 2025 was -$145.5 million (down 749.92% YoY), and the annual figure for FY2025 was -$144.3 million, down 750.08%.
  • EBIAT for Q4 2025 was -$278.5 million at Charles River Laboratories International, down from $54.4 million in the prior quarter.
  • Over the last five years, EBIAT for CRL hit a ceiling of $187.1 million in Q4 2023 and a floor of -$278.5 million in Q4 2025.
  • Median EBIAT over the past 5 years was $91.4 million (2021), compared with a mean of $61.9 million.
  • Biggest five-year swings in EBIAT: skyrocketed 54.76% in 2022 and later tumbled 214.65% in 2024.
  • Charles River Laboratories International's EBIAT stood at $145.4 million in 2021, then grew by 25.64% to $182.7 million in 2022, then increased by 2.39% to $187.1 million in 2023, then tumbled by 214.65% to -$214.5 million in 2024, then decreased by 29.82% to -$278.5 million in 2025.
  • The last three reported values for EBIAT were -$278.5 million (Q4 2025), $54.4 million (Q3 2025), and $52.7 million (Q2 2025) per Business Quant data.